28.92 USD
-0.02 (-0.07%)
28.92 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 71% to MRSN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.86. This target is 17.1% above the current price.
MRSN was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about MRSN.
In the last month the buy percentage fell by 16 points. So the trust of analysts is decreasing.
MRSN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-11-13 | BTIG | Downgrade | Buy -> Neutral |
| 2025-11-13 | Truist Securities | Downgrade | Buy -> Hold |
| 2025-08-14 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-16 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-16 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-06 | William Blair | Initiate | Outperform |
| 2024-08-27 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-14 | Baird | Maintains | Neutral -> Neutral |
| 2024-03-19 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-29 | Guggenheim | Upgrade | Neutral -> Buy |
| 2024-02-29 | Wedbush | Upgrade | Neutral -> Outperform |
| 2024-02-29 | Truist Securities | Upgrade | Hold -> Buy |
| 2024-02-29 | Baird | Maintains | Neutral -> Neutral |
| 2023-12-04 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-07-28 | Baird | Downgrade | Outperform -> Neutral |
| 2023-07-28 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-07-27 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-07-27 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-06-16 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-06-16 | Citigroup | Maintains | Buy -> Buy |
| 2023-06-15 | Guggenheim | Initiate | Buy |
| 2023-05-11 | Citigroup | Maintains | Buy |
| 2023-03-16 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2022-11-21 | Truist Securities | Initiate | Buy |
| 2022-08-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-09 | Baird | Maintains | Outperform |
| 2022-05-09 | SVB Leerink | Maintains | Outperform |
| 2022-02-18 | SVB Leerink | Maintains | Outperform |
MERSANA THERAPEUTICS INC / MRSN FAQ
Can you provide the average price target for MERSANA THERAPEUTICS INC stock?
14 analysts have analysed MRSN and the average price target is 33.86 USD. This implies a price increase of 17.1% is expected in the next year compared to the current price of 28.92.
How do analysts rate MERSANA THERAPEUTICS INC (MRSN)?
The consensus rating for MERSANA THERAPEUTICS INC (MRSN) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.